Patents by Inventor Tuna Mutis

Tuna Mutis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240117064
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 11, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240076397
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 7, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230399414
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: December 14, 2023
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D.CHAMULEAU, Tuna MUTIS
  • A COMPOSITION OF ANTI-DR5 ANTIBODIES AND AN IMMUNOMODULATORY IMIDE DRUG FOR USE IN TREATING MULTIPLE MYELOMA
    Publication number: 20230293680
    Abstract: The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.
    Type: Application
    Filed: July 23, 2021
    Publication date: September 21, 2023
    Inventors: Hilma VAN DER HORST, Tuna MUTIS, Kristin STRUMANE, Esther BREIJ, Marije OVERDIJK
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11512137
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 29, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220251231
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: November 23, 2021
    Publication date: August 11, 2022
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • NOVEL ANTICANCER DRUG FL118 FORMULATION IN COMBINATION WITH IMMUNOTHERAPY FOR TREATMENT OF HUMAN CANCER
    Publication number: 20220249464
    Abstract: Described herein, are the extended and newly discovered novel formulations of FL118 used alone or in combination with a type of cancer immunotherapy including but not be limited to, cell-based immunotherapy, antigen-based immunotherapy, cytokine-based immunotherapy, immunomodulatory therapy and other agents-based immunotherapy or their combinations in a certain way, ant sequential regimens or schedules, for cancer treatment to preclude, eliminate or reverse cancer phenotypes and treatment resistance.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 11, 2022
    Inventors: Tuna Mutis, Lisa Holthof, Fengzhi Li, Xiang Ling, Jianqun Liao
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11396553
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: July 26, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20210403592
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: May 24, 2021
    Publication date: December 30, 2021
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • ANTI-CD37 ANTIBODIES AND ANTI-CD20 ANTIBODIES, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210371539
    Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 2, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Ronald TAYLOR, Margaret LINDORFER, Hilma VAN DER HORST, Martine E. D. CHAMULEAU, Tuna MUTIS, Paul PARREN, Esther BREIJ
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210355232
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11034772
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: June 15, 2021
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
    Patent number: 11021543
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210024647
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200291124
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: May 11, 2020
    Publication date: September 17, 2020
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200270359
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 27, 2020
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
    Patent number: 10668149
    Abstract: The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Parul Doshi, Henk M. Lokhorst, Tuna Mutis
  • Combination therapies with anti-CD38 antibodies
    Patent number: 10604580
    Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 31, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Henk M. Lokhorst, Tuna Mutis, Inger S Nijhof, Niels Van de Donk
  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20190144557
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: October 16, 2018
    Publication date: May 16, 2019
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • Combination Therapies with Anti-CD38 Antibodies
    Publication number: 20170107295
    Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 20, 2017
    Inventors: Henk M. Lokhorst, Tuna Mutis, Inger S Nijhof, Niels Van de Donk